Mitochondrial Genotoxicity of Hepatitis C Treatment among People Who Inject Drugs
- PMID: 34768343
- PMCID: PMC8584601
- DOI: 10.3390/jcm10214824
Mitochondrial Genotoxicity of Hepatitis C Treatment among People Who Inject Drugs
Abstract
Antiviral nucleoside analogues (ANA) are newly used therapeutics acting against the hepatitis C virus (HCV). This class of drug is well known to exhibit toxicity on mitochondrial DNA (mtDNA). People who inject drugs (PWID) are particularly affected by HCV infection and cumulated mitotoxic drug exposure from HIV treatments (antiretrovirals, ARV) and other illicit drugs. This study aims to explore the impact of direct-acting antiviral (DAA) treatments on mtDNA among PWID. A total of 470 actively injecting heroin users were included. We used quantitative PCR on whole blood to determine the mitochondrial copy number per cell (MCN) and the proportion of mitochondrial DNA deletion (MDD). These parameters were assessed before and after DAA treatment. MDD was significantly increased after HCV treatment, while MCN did not differ. MDD was even greater when subjects were cotreated with ARV. In multivariate analysis, we identified that poly-exposure to DAA and daily heroin injection or regular consumption of methamphetamines were positively associated with high MCN loss while DAA and ARV treatments or methadone use were identified as risk factors for having mtDNA deletion. These observations deserve attention since they were previously associated with premature cell ageing or cell transformation and therefore call for a long-term follow-up.
Keywords: HCV treatment; drug users; genotoxicity; mitochondria.
Conflict of interest statement
The authors declare no conflict of interest.
References
-
- Ghany M.G., Morgan T.R. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Dis-eases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2020;71:686–721. doi: 10.1002/hep.31060. - DOI - PMC - PubMed
-
- World Health Organization (WHO) Viral Hepatitis 2016–2021: Towards Ending Viral Hepatitis. [(accessed on 28 September 2021)]. Available online: https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-....
-
- Nelson D.R., Zeuzem S., Andreone P., Ferenci P., Herring R., Jensen D.M., Marcellin P., Pockros P.J., Rodríguez-Torres M., Rossaro L., et al. Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients. Ann. Hepatol. 2012;11:15–31. doi: 10.1016/S1665-2681(19)31482-6. - DOI - PMC - PubMed
-
- Feng J.Y., Xu Y., Barauskas O., Perry J.K., Ahmadyar S., Stepan G., Yu H., Babusis D., Park Y., McCutcheon K., et al. Role of mitochondrial RNA polymerase in the toxicity of nucleotide inhibitors of hepatitis C virus. Antimicrob. Agents Chemother. 2016;60:806–817. doi: 10.1128/AAC.01922-15. - DOI - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
